M. Potenza

Low-risk thyroid carcinoma: when is the treatment worse than the disease?

J. Mechanick, M. Potenza, 2009, Expert review of endocrinology & metabolism.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Michael A. Via, T. Araki, M. Potenza, 2009 .

Excess thyroid hormone and carbohydrate metabolism.

Michael A. Via, Robert T. Yanagisawa, M. Potenza, 2009, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Male hypogonadism: The unrecognized cardiovascular risk factor.

M. Shimshi, M. Potenza, 2008, Journal of clinical lipidology.

The metabolic syndrome: definition, global impact, and pathophysiology.

J. Mechanick, M. Potenza, 2009, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

Ablation of right and left atrial premature beats following cardioversion in patients with chronic atrial fibrillation refractory to antiarrhythmic drugs.

A. Natale, S. Beheiry, G. Tomassoni, 2000, The American journal of cardiology.

The influence of age, gender, and race on the prevalence of depression in heart failure patients.

Brian Baker, Erika Friedmann, M. Fisher, 2004, Journal of the American College of Cardiology.

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Michael A. Via, T. Araki, M. Potenza, 2010, Diabetes, metabolic syndrome and obesity : targets and therapy.

Intravenous Ibandronate Acutely Reduces Bone Hyperresorption in Chronic Critical Illness

Michael A. Via, J. Mechanick, Li Sun, 2012, Journal of intensive care medicine.

Targeting the incretin system in type 2 diabetes mellitus.

E. Rayfield, M. Potenza, 2009, The Mount Sinai journal of medicine, New York.